Catalyst Wire Dossier Catalyst Wire Dossier

FG-3019 (pamrevlumab)

pamrevlumab · FibroGen, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FG-3019 (pamrevlumab), covering 2014-08-06 to 2014-08-06. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer [Phase 1]

See pricing